The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2

Clinical and Vaccine Immunology

Volumn 18, Issue 3, 2011, Pages 455-459

  Valdés, Iris ^a   Gil, Lázaro ^a   Romero, Yaremis ^a   Castro, Jorge ^a   Puente, Pedro ^a   Lazo, Laura ^a   Marcos, Ernesto ^a   Guzmán, María G ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CHIMERIC PROTEIN; DENGUE VACCINE; DENGUE VIRUS SEROTYPE 2 DOMAIN III CAPSID PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS 2; HAPLORHINI; INFECTION PREVENTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROVOCATION TEST; VIRUS ATTENUATION; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID; CERCOPITHECUS AETHIOPS; DENGUE VACCINES; DENGUE VIRUS; IMMUNIZATION, SECONDARY; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 79952544208     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00382-10     Document Type: Article

References (31)

1. Bernardo, L., et al. 2008. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 80:194-199.
2. Burke, D. S., and T. P. Monath. 2001. Flaviviruses, p. 1043-1125. In D. M. Knipe et al. (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Chen, Y., T. Maguire, and R. M. Marks. 1996. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70:8765-8772.
4. Chin, J. F., J. J. Chu, and M. L. Ng. 2007. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9:1-6.
5. Churdboonchart, V., N. Bhamarapravati, and S. Peampramprecha. 1991. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 44:481-493.
6. Crill, W. D., H. R. Hughes, M. J. Delorey, and G. J. Chang. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:4991-5009.
7. Crill, W. D., and J. T. Roehrig. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773.
8. Dejnirattisai, W., et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
9. Gil, L., et al. 2009. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol. 22:23-29.
10. Gil, L., et al. 2009. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int. Immunol. 21:1175-1183.
11. Gubler, D. J. 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:100-103.
12. Guirakhoo, F., et al. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccine 2:60-67. (Pubitemid 43927159)
13. Guy, B., et al. 2008. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26:5712-5721.
14. Hermida, L., et al. 2006. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24:3165-3171.
15. Hermida, L., et al. 2004. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115:41-49. (Pubitemid 37500961)
16. Hermida, L., et al. 2004. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 39:107-114.
17. Hung, J. J., et al. 2004. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 78:378-388.
18. Kitchener, S., et al. 2006. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-1241. (Pubitemid 43222030)
19. Martín, J., et al. 2009. Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol. Immunol. 53:216-223.
20. Martín, J., et al. 2009. Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr. Microbiol. 59:579-583.
21. Morens, D. M., S. B. Halstead, and P. M. Repik. 1985. Simplified plaque reduction assay for dengue viruses by semimicro methods in BHK 21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22:250-254.
22. Morrison, D., et al. 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201:370-377.
23. Sabchareon, A., et al. 2004. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23:99-109.
24. Simasathien, S., et al. 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 78:426-433.
25. Simmons, M., T. Burgess, J. Lynch, and R. Putnak. 2010. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:280-288.
26. Valdés, I., et al. 2009. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394:249-258.
27. Valdés, I., et al. 2010. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int. J. Infect. Dis. 14:377-383.
28. Valdés, I., et al. 2009. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitides. Vaccine 27:995-1001.
29. Van der Most, R. G., K. Murali-Krishna, R. Ahmed, and J. H. Strauss. 2000. Chimeric yellow fever/ dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 4:8094-8101.
30. Wahala, W. M., A. A. Kraus, L. B. Haymore, M. A. Accavitti-Loper, and A. M. de Silva. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113.
31. Yauch, L. E., et al. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182:4865-4873.